AYA.AX Artrya Limited ASX A$3.23 intraday 21 Feb 2026: AI diagnosis vs cash burn

AYA.AX stock trades at A$3.23 intraday on 21 Feb 2026, with a trading range today of A$3.16–A$3.32. Investors are weighing Artrya Limited’s AI-powered Salix diagnostic traction against stretched valuation ratios and negative earnings. The company shows a market cap of A$373,956,000.00, EPS of -0.18, and PE of -18.33, so near-term moves will follow earnings news and adoption signals for its coronary CT AI tool.

AYA.AX stock: Intraday price and technical snapshot

AYA.AX stock is at A$3.23 with volume 200,235.00 shares versus an average volume of 682,885.00. Technical indicators show RSI 40.80 and ADX 27.45, signalling a firm trend but weaker momentum. The 50-day average is A$4.03 and the 200-day average is A$2.43, so short-term bias is mixed while longer-term trend remains constructive.

AYA.AX stock: Financials, valuation and cash metrics

Artrya reports EPS -0.18 and market cap A$373,956,000.00, with a price-to-book of 15.97 and PB ratio 15.97. Key ratios show current ratio 8.27 and cash per share A$0.11, which supports near-term liquidity but underlines limited revenue per share (0.00). High R&D-to-revenue and negative margins remain valuation headwinds for AYA.AX stock.

AYA.AX stock: AI product, market opportunity and sector context

Artrya’s Salix automates coronary artery disease detection from CT scans and targets diagnostic workflows in cardiology. The Healthcare sector on ASX has average PB 3.98, so AYA.AX stock trades at a premium to peers. Adoption milestones and hospital contracts will drive revenue growth for the AI business model and are the primary near-term catalysts.

AYA.AX stock: Meyka AI rates AYA.AX with a score out of 100

Meyka AI rates AYA.AX with a score out of 100: 63.36, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating balances strong technology potential against negative profitability. These grades are not guaranteed and we are not financial advisors.

AYA.AX stock: Risks, catalysts and price targets

Key risks for AYA.AX stock include slow hospital rollouts, regulatory delays and continued negative EPS. Catalysts are recurring revenue wins, strong clinical validation and the earnings announcement on 24 Feb 2026. Meyka AI’s forecast model projects yearly A$7.83, a quarterly near-term level A$5.03, and monthly A$3.09. Use the quarterly A$5.03 as a conservative 12-month target and the yearly A$7.83 as an upside case, noting execution risk.

Final Thoughts

AYA.AX stock sits at A$3.23 intraday on 21 Feb 2026 with a clear growth-versus-profit trade-off. The company’s AI diagnostic product gives it scalable revenue potential inside the Healthcare sector, but valuation and negative earnings create sensitivity to execution. Meyka AI’s forecast model projects a 12-month target of A$7.83, implying an upside of 142.31% from today’s price; the monthly model of A$3.09 implies a short-term downside of -4.33%. Investors should watch the earnings release on 24 Feb 2026, adoption announcements, and 50-day moving average behaviour. For active traders focused on AI stocks, AYA.AX stock offers pronounced upside if growth accelerates, but remains a hold for risk-averse portfolios until revenue consistency appears. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.